JY207

JY207: sourced facts only. name: "Furthermore, JY207 does not bind to human red blood cells, but preferentially binds to CD47/PD-L1 double positive tumor cells, thus reduces the possibility of on-target toxicities." [DOI:10.1158/1538-7445.am2023-6307]; target: "Furthermore, JY207 does not bind to human red blood cells, but preferentially binds to CD47/PD-L1 double positive tumor cells, thus reduces the possibility of on-target toxicities." [DOI:10.1158/1538-7445.am2023-6307]; target: "Furthermore, JY207 does not bind to human red blood cells, but preferentially binds to CD47/PD-L1 double positive tumor cells, thus reduces the possibility of on-target toxicities." [DOI:10.1158/1538-7445.am2023-6307]; developer: "1Shenzhen Enduring Biotech, Ltd., Shenzhen, China." [DOI:10.1158/1538-7445.am2023-6307]; modality: "In this study, we reveal another novel pegylated P-BsADC (JY207) formed by site-specific conjugation of a bispecific single chain fusion protein targeting PD-L1 and CD47 with PEG-MMAE (a pegylated cytotoxic payload MMAE)." [DOI:10.1158/1538-7445.am2023-6307]